Argos_blog_postThe Durham Chamber of Commerce began working to keep Argos in Durham back in 2010 and faced challenging competition from Canada along with cities in Texas, Florida and North Carolina.  As with most successful economic development deals, the Durham Chamber of Commerce collaborated closely with the State of North Carolina, the North Carolina Biotechnology Center, North Carolina State University, North Carolina Central University’s BRITE Center, Duke University, Durham County, the City of Durham and Durham Technical Community College.

Durham’s hometown biopharmaceutical company, Argos Therapeutics, a leader in the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform, announced plans for development of a state of the art biomanufacturing facility in Research Triangle Park.  The company plans to investment more that $57 million to build and supply its nearly 100,000 square foot facility and has retained the construction services of the Keith Corporation. Having approximately 100 employees working in Durham, the Durham Chamber is delighted that Argos will be staying and growing here, and has plans to hire 236 additional employees.

The new facility will be used to support automated production of the company’s argos_building
Arcelis®-based personalized immunotherapy product candidates, beginning with AGS-003, the company’s lead oncology product candidate, currently being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma.  The technology for Argos’ technology platform was spun out of Duke University back in the 1990’s. From that beginning, it has grown to be a publicly traded company that is paving the way toward a new generation of medical treatment.